U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07947277) titled 'First-Line Nivolumab Plus Ipilimumab or Cabozantinib Followed by Second-Line Lenvatinib Plus Everolimus in Metastatic TFE-Rearranged Renal Cell Carcinoma' on Nov. 12.
Brief Summary: This randomized phase 2 study evaluates the efficacy and safety of nivolumab plus ipilimumab versus nivolumab plus cabozantinib as first-line treatment in patients with metastatic TFE-rearranged renal cell carcinoma. Patients are randomly assigned to one of the two treatment groups. Following disease progression, patients receive protocol-specified second-line treatment with lenvatinib plus everolimus. The study assesses treatment outcomes during first-l...